Delta variant behind 86% of India's 'breakthrough' cases during COVID-19 second wave: ICMR study

-

The Delta variant of SARS-COV-2 was the major reason for breakthrough infections during the second wave of COVID-19 pandemic in the country, but only 9.8 percent cases required hospitalisation and fatality was observed in only 0.4 percent cases, a new study conducted by the Indian Council of Medical Research has shown.

The study, "Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India", is the first such analysis on breakthrough infections post-vaccination. It was published on the preprint server medRxiv on Friday, and is yet to be peer-reviewed, reported the Indian Express.

Breakthrough infections are those cases where a person gets infected even after getting vaccinated.

The study indicated that majority of the clinical cases in the breakthrough were infected with the Delta variant in India. However, the death rate among vaccinated individuals was found to be low.

The researchers tracked 677 individuals from 17 states and Union Territories who contracted the disease even after being vaccinated. Sixty-seven of these cases (9.8 percent) required hospitalization while, three of them died.

"Only 9.8% cases required hospitalization while fatality was observed in only 0.4% cases," the study reported, adding "This clearly suggests that the vaccination does provide reduction in hospital admission and mortality."

The ICMR study is a clinical characterisation and genomic analysis of COVID-19 positive cases who had taken one or two doses of the vaccine before they caught the infection

What are the important findings of the ICMR study

  • The overall majority (86.09 percent) of the breakthrough infections were caused by the Delta variant (B.1.617.2)
  • The study found that southern, western, eastern, and north-western regions of India predominantly reported breakthrough infections from mainly Delta and then Kappa variant of SARS-CoV-2
  • Of the 677 patients analysed, 85 caught the infection after taking the first dose of the vaccine, while 592 were infected after receiving both the doses
  • A total of 482 cases (71%) were symptomatic with one or more symptoms, while 29% had asymptomatic SARS-CoV-2 infection
  • Fever was the most consistent presentation (69 percent), followed by body ache including headache and nausea (56 percent), cough (45 percent), sore throat (37 percent) loss of smell and taste (22 percent), diarrhoea (6 percent), breathlessness (6 percent) and 1 percent had ocular irritation and redness
  • A total of 604 patients had received Covishield vaccine, 71 had received Covaxin and two were vaccinated with Sinopharm
  • A total 511 SARS-CoV-2 genomes were recovered, and an analysis determined that 443 (86.69 percent) were of the Delta variant (B.1.617.2) that was first detected in India last year
  • Delta was predominant in samples from across India except the northern region, where Alpha (B.1.1.7, which was first detected in the United Kingdom) was predominant, the study says
  • The present study revealed the infection among breakthrough cases predominantly occurred through Delta variants indicating its high community transmission during March-June followed by Alpha and Kappa variants
  • The 17 states and Union Territories from where the samples were collected are Maharashtra, Kerala, Gujarat, Uttarakhand, Karnataka, Manipur, Assam, Jammu and Kashmir, Chandigarh, Rajasthan, Madhya Pradesh, Punjab, Puducherry, New Delhi, West Bengal, Tamil Nadu and Jharkhand
  • The study found that southern, western, eastern and north-western regions of India predominantly reported breakthrough infections from mainly Delta and then Kappa variant of SARS-CoV-2


from Firstpost India Latest News https://ift.tt/2UQm1Yb
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more